Close

Not a member yet? Register now and get started.

lock and key

Sign in to your account.

Account Login

Forgot your password?

Healthcare  // Browsing posts in Healthcare

Exact Sciences Idea Proposal (EXAS)

Exact Sciences Idea Proposal (EXAS)

Will the inclusion of Cologuard in the 2017 HEDIS quality measures drive growth for Exact Sciences? Report Available:August 31, 2016   Blueshift’s initial research shows that momentum for Cologuard, EXAS’s colon cancer screening test, has picked up recently as a governing body clarified language that the test is on equal standing among other screening tests, […]

Read more...

Jun 24 2016 Biotechnology, Healthcare

NVDQ’s DermACELL On Track to Achieve 2016 Sales Goal of $10 Million

Research Question: Will Novadaq grow DermACELL sales to $10 million in 2016 and $50 million or more by 2018? Companies: AGN, IART, JNJ, MDXG, NVDQ, NVS, OSIR By: David Franklin Click here to download the report (.pdf)   Summary of Findings DermACELL, an acellular dermal matrix (ADM) tissue that is used primarily in breast reconstruction, is likely […]

Read more...

Perrigo Recovery Will Happen, Expected to Take Time

Research Question: Will Perrigo recover from a recent string of negative developments to see growth over the short and long term in its three main business lines? Companies: GSK, JNJ, MYL, PRGO, TEVA By: David Franklin Click here to download the report (.pdf)   Summary of Findings Perrigo Co. plc (PRGO) is expected to recover over time […]

Read more...

Perrigo Idea Proposal

Perrigo Idea Proposal

Will Perrigo recover from a recent string of negative developments to see short and long term growth in its three main business lines? Report Available: June 10, 2016   Blueshift’s initial research shows uncertainty in the quality of PRGO’s business and their long term trajectory. The company pre-announced Q1 earnings and revenue below Street expectations […]

Read more...

Novadaq Idea Proposal

Novadaq Idea Proposal

Will Novadaq successfully grow DermACELL sales to $50 million or more by 2018? Report Available: June 23, 2016   Blueshift’s initial research shows sales of NVDQ’s DermACELL, its acellular dermal matrix (ADM) product used primarily in breast reconstruction, increasing as it becomes part of the company’s fastest growing segment. Management expects it to reach about $10 […]

Read more...

Teleflex’s Premium Pricing Strategy Will Prevail Despite Challenges

Research Question: Will hospitals continue to accept price hikes for Teleflex’s vascular products when competitors are dropping prices? Companies: ABMD, ANGO, BCR, BDX, BSX, CAH, CFN, EW, JNJ, KRX:005935, MDT, MMSI, STJ, TFX, TYO:4543 By: David Franklin Click here to download the report (.pdf)   Summary of Findings Teleflex ’s (TFX) strategy of premium pricing […]

Read more...

Apr 08 2016 Pharmaceuticals

Market Ready to Adopt Long-Acting Buprenorphine As Opioid Treatment Option

Research Question:Will long-acting implantable and injectable buprenorphine become widely adopted for opioid addiction treatment? Companies: ALKS, BDSI, HRTX, LON:INDV, STO:CAMX, STO:ORX, TLV:TEVA, TSX:GUD, TTNP By: David Franklin Click here to download the report (.pdf)   Summary of Findings Long-acting implantable and injectable buprenorphine is expected to become an important tool and gain a significant foothold […]

Read more...

Teleflex Idea Proposal

Teleflex Idea Proposal

Will hospitals continue to accept price hikes for Teleflex’s vascular products when competitors are dropping prices? Report Available: April 20, 2016   Blueshift’s initial research shows TFX has benefited from a broad healthcare/medical device product line, a deep product pipeline, and the ability to command higher prices than the competition. With the healthcare spending growth […]

Read more...

Buprenorphine Opioid Addiction Treatment Idea Proposal

Buprenorphine Opioid Addiction Treatment Idea Proposal

Will long acting implantable and injectable buprenorphine become widely adopted for opioid addiction treatment? Report Available: April 8, 2016   Blueshift’s initial research shows that addiction to opioids has skyrocketed to the point of being an epidemic. Current available treatment options face numerous challenges including frequent dosing, poor adherence, high incidence of relapse, and misuse. […]

Read more...

Early Warning for ZLTQ’s CoolSculpting: CYNO’s SculpSure Could Cut into Next Year’s Share

Research Question: Can Zeltiq’s CoolSculpting system continue to fend off competitors with similar or superior body contouring products? Companies: AGN, CUTR, CYNO, ELOS, LMNS, NUS, TSE:VRX, ZLTQ By: David Franklin Click here to download the report (.pdf)   Summary of Findings Zeltiq Aesthetics Inc.’s (ZLTQ) CoolSculpting now faces competition from Cynosure Inc.’s (CYNO) recently approved SculpSure […]

Read more...